Pharmaceutical compositions of testosterone
The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone.
1. An injectable pharmaceutical composition comprising:
(i) about 200 mg/mL of testosterone cypionate;
(ii) 15 mg/mL to 25 mg/mL of benzyl alcohol;
(iii) about 220 mg/mL to about 225 mg/mL of benzyl benzoate; and
(iv) cotton seed oil,
wherein the testosterone cypionate is the only active ingredient in the pharmaceutical composition;
wherein the composition is sterilized and suitable for intramuscular injection; and
wherein the composition does not exhibit crystal formation.
2. The pharmaceutical composition according to claim 1 , wherein the composition has been aged in containers for at least 48 hours at a temperature of about 20° C. to about 60° C. prior to storage, and wherein the composition does not exhibit crystal formation for 6 months when stored at a temperature of about 2° C. to about 8° C.
3. A method for preparing the pharmaceutical composition according to claim 1 , comprising:
(i) providing a pharmaceutical composition comprising about 200 mg/mL testosterone cypionate, cotton seed oil, 15 mg/mL to 25 mg/mL of benzyl alcohol, and about 220 mg/mL to about 225 mg/mL of benzyl benzoate, and
(ii) ageing the composition for at least 48 hours at a temperature of about 20° C. to about 60° C.
4. The method according to claim 3 , which comprises ageing the composition for at least 48 hours at a temperature of about 20° C. to about 25° C.
5. A method of treatment, comprising administering the pharmaceutical composition according to claim 1 to a patient in need of hormone replacement therapy, wherein the patient has a condition associated with symptoms of deficiency or absence of endogenous testosterone.
6. The pharmaceutical composition according to claim 1 , wherein the composition does not exhibit crystal formation for 6 months when stored at a temperature of about 10° C. to about 15° C.